Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer
Cogstate, a leading neuroscience technology company, has appointed Dr. Kaycee Sink as Chief Medical Officer. Dr. Sink, formerly Principal Medical Director in Neurodegeneration at Genentech, brings extensive experience in Alzheimer's disease drug development. In her new role, she will:
- Lead Cogstate's support of clinical trials in Alzheimer's and other neurodegenerative disorders
- Advance innovations to improve data quality and trial efficiency
- Advise biopharmaceutical leaders on trial design, endpoint selection, and data quality
- Support efforts to commercialize cognitive assessment technologies for timely diagnoses
Dr. Sink's appointment aims to strengthen Cogstate's value in accelerating Alzheimer's therapeutics development and expanding treatment options. She brings over 20 years of experience in clinical care and research in aging and neurodegenerative disorders.
Cogstate, una delle principali aziende di tecnologia neuroscientifica, ha nominato Dr. Kaycee Sink come Chief Medical Officer. Il Dr. Sink, precedentemente Direttore Medico Principale in Neurodegenerazione presso Genentech, porta un'ampia esperienza nello
- Guidare il supporto di Cogstate per le sperimentazioni cliniche sull'Alzheimer e altre malattie neurodegenerative
- Promuovere innovazioni per migliorare la qualità dei dati e l'efficienza delle sperimentazioni
- Consigliare i leader biofarmaceutici sulla progettazione degli studi, selezione degli endpoint e qualità dei dati
- Sostenere gli sforzi per commercializzare le tecnologie di valutazione cognitiva per diagnosi tempestive
La nomina del Dr. Sink mira a rafforzare il valore di Cogstate nell'accelerare lo sviluppo di terapie per l'Alzheimer e ampliare le opzioni di trattamento. Porta con sé oltre 20 anni di esperienza nella cura clinica e nella ricerca nell'invecchiamento e nelle malattie neurodegenerative.
Cogstate, una empresa líder en tecnología de neurociencia, ha nombrado Dr. Kaycee Sink como Directora Médica. La Dra. Sink, anteriormente Directora Médica Principal en Neurodegeneración en Genentech, aporta una amplia experiencia en el desarrollo de fármacos para la enfermedad de Alzheimer. En su nuevo rol, ella:
- Dirigirá el apoyo de Cogstate a ensayos clínicos sobre Alzheimer y otros trastornos neurodegenerativos
- Avanzará innovaciones para mejorar la calidad de los datos y la eficiencia de los ensayos
- Asesorará a los líderes biofarmacéuticos sobre el diseño de ensayos, selección de puntos finales y calidad de los datos
- Apoyará los esfuerzos para comercializar tecnologías de evaluación cognitiva para diagnósticos oportunos
El nombramiento de la Dra. Sink tiene como objetivo fortalecer el valor de Cogstate en la aceleración del desarrollo de terapias para el Alzheimer y ampliar las opciones de tratamiento. Aporta más de 20 años de experiencia en atención clínica e investigación en envejecimiento y trastornos neurodegenerativos.
Cogstate는 신경 과학 기술 분야의 선두 기업으로 Dr. Kaycee Sink를 최고 의료 책임자로 임명하였습니다. Sink 박사는 이전에 Genentech에서 신경퇴행성 질환의 주 의료 이사로 재직하며 알츠하이머병 약물 개발 분야에서 광범위한 경험을 가지고 있습니다. 그녀는 새로운 역할에서 다음을 수행할 것입니다:
- Cogstate의 알츠하이머 및 기타 신경퇴행성 질환의 임상 시험 지원을 이끌 것입니다.
- 데이터 품질과 시험 효율성을 개선하기 위한 혁신을 추진할 것입니다.
- 임상시험 설계, 종결점 선정 및 데이터 품질에 대해 생명공학 제약 업계의 리더들에게 조언할 것입니다.
- 시기적절한 진단을 위한 인지 평가 기술 상용화 노력을 지원할 것입니다.
Sink 박사의 임명은 Cogstate가 알츠하이머 치료제 개발을 가속화하고 치료 옵션을 확대하는 데 가치를 더하기 위한 것입니다. 그녀는 노화와 신경퇴행성 질환에 대한 임상 관리 및 연구 분야에서 20년 이상의 경험을 제공합니다.
Cogstate, une entreprise leader dans la technologie en neurosciences, a nommé Dr. Kaycee Sink au poste de Directrice Médicale. Le Dr Sink, anciennement Directrice Médicale Principale en Neurodégénérescence chez Genentech, apporte une vaste expérience dans le développement de médicaments pour la maladie d'Alzheimer. Dans son nouveau rôle, elle va :
- Diriger le soutien de Cogstate aux essais cliniques sur la maladie d'Alzheimer et d'autres troubles neurodégénératifs
- Faire avancer des innovations visant à améliorer la qualité des données et l'efficacité des essais
- Conseiller les leaders bio-pharmaceutiques sur la conception des essais, la sélection des critères d'évaluation et la qualité des données
- Soutenir les efforts de commercialisation des technologies d'évaluation cognitive pour des diagnostics en temps opportun
La nomination du Dr Sink vise à renforcer la valeur de Cogstate en accélérant le développement des thérapies pour la maladie d'Alzheimer et en élargissant les options de traitement. Elle apporte plus de 20 ans d'expérience dans les soins cliniques et la recherche sur le vieillissement et les troubles neurodégénératifs.
Cogstate, ein führendes Unternehmen in der Neurowissenschaftstechnologie, hat Dr. Kaycee Sink zur Chief Medical Officer ernannt. Dr. Sink, zuvor Principal Medical Director für Neurodegeneration bei Genentech, bringt umfangreiche Erfahrung in der Entwicklung von Alzheimer-Medikamenten mit. In ihrer neuen Rolle wird sie:
- Cogstates Unterstützung klinischer Studien zu Alzheimer und anderen neurodegenerativen Erkrankungen leiten
- Innovationen vorantreiben, um die Datenqualität und die Effizienz der Studien zu verbessern
- Bio-pharmazeutische Führungskräfte in Bezug auf Studiendesign, Auswahl von Endpunkten und Datenqualität beraten
- Bemühungen unterstützen, kognitive Bewertungs Technologien für eine zeitnahe Diagnose zu commercialisieren
Die Ernennung von Dr. Sink zielt darauf ab, den Wert von Cogstate bei der Beschleunigung der Entwicklung von Alzheimer-Therapeutika zu stärken und die Behandlungsoptionen zu erweitern. Sie bringt über 20 Jahre Erfahrung in der klinischen Versorgung und Forschung in den Bereichen Alterung und neurodegenerative Erkrankungen mit.
- Appointment of Dr. Kaycee Sink as Chief Medical Officer, bringing extensive experience in Alzheimer's disease drug development
- Potential for improved support of clinical trials in Alzheimer's and other neurodegenerative disorders
- Possible advancements in data quality and trial efficiency for more accurate studies
- Potential for accelerated development of new Alzheimer's disease therapeutics
- Expansion of Cogstate's expertise in neurodegenerative disorders
- None.
Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Cogstate, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.
Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial design decisions, endpoint selection, and data quality considerations for cognitive and clinical outcome assessments.
Dr. Sink will also play a critical role in Cogstate’s efforts to commercialize cognitive assessment technologies within the community to support timely and more accurate diagnoses in healthcare.
“We are delighted to welcome Dr. Sink to Cogstate,” said Brad O’Connor, Cogstate CEO. “The medical, research, and pharmaceutical development expertise she brings will strengthen the value we offer our customers who seek to accelerate the development of new Alzheimer’s disease therapeutics, expand treatment options for patients, and make brain health awareness and action a normal part of aging.”
Dr. Sink joins Cogstate from Genentech (part of the Roche group of companies) where she was Principal Medical Director in Neurodegeneration, having leadership roles in the late-stage development of several molecules being studied for Alzheimer’s disease and other neurodegenerative disorders as well as digital applications for the same. She joined Genentech in 2017 after 13 years on faculty at Wake Forest School of Medicine, where she rose to tenured Full Professor of Medicine, Neurology, and Public Health Sciences.
“Cogstate’s commitment to bring technology and science to improve brain health assessment and to look at Alzheimer’s disease in a holistic manner is very exciting,” said Dr. Sink. “I’m thrilled to join this team of scientific and operational experts and contribute my passion to the evolving healthcare and research landscape in support of getting the right treatment to the right patients at the right time.”
Dr. Sink is board certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in aging, Alzheimer’s disease, and other neurodegenerative disorders. She obtained her medical degree at the University of CA, San Francisco, and subsequently trained in internal medicine followed by clinical and research fellowships in geriatrics, also at UCSF.
Dr. Sink continues to see patients and teach in the Memory Assessment Clinic as adjunct faculty at Wake Forest School of Medicine in Winston Salem, NC.
About Cogstate
Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. Cogstate provides rapid, reliable and highly sensitive digital cognitive tests and supports electronic clinical outcome assessment (eCOA) solutions. Cogstate also offers quality assurance services for clinical trial endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For more information, please visit www.cogstate.com.
FAQ
Who is the new Chief Medical Officer of Cogstate (COGZF)?
What is Dr. Kaycee Sink's background before joining Cogstate (COGZF)?
How will Dr. Sink's appointment impact Cogstate's (COGZF) Alzheimer's disease research?
What are Dr. Sink's main responsibilities as Chief Medical Officer at Cogstate (COGZF)?
